Search This Blog

Thursday, June 19, 2025

Skye confirms phase 2 data on nimacimab for obesity expected later this year

 Phase 2a data on Skye Bioscience's (NASDAQ:SKYE) cannabinoid-1 receptor blocker (CB1) for obesity, nimacimab, should be released in late Q3

https://seekingalpha.com/news/4459791-skye-confirms-phase-2-data-nimacimab-obesity-expected-later-this-year

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.